araag2/HINT huggingface dataset:
Clinical trial NCT00327808 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: tpi-1020, budesonide
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 18 through 65 years of age.

          -  Smoking history of more than 5 pack/years but less than 25 pack/years and who have no
             desire to quit smoking despite physician's advice and who currently smoke at least 5
             cigarettes per day.

          -  Mild to moderate, stable, allergic asthma as defined by American Thoracic Society
             (ATS) criteria 1

          -  History of episodic wheeze and shortness of breath

          -  Subjects currently and only receiving inhaled short-acting bronchodilator treatment
             for asthma.

        Exclusion Criteria:

          -  History or symptoms of significant autoimmune, hematological, or neurological disease,
             including transient ischemic attack (TIA), stroke, seizure disorder, or behavioural
             disturbances that are judged clinically significant by the Investigator

          -  History of serious adverse reaction or hypersensitivity to corticosteroids

          -  Abnormal chest X-ray that is judged clinically significant

          -  Pregnant or lactating or have positive plasma pregnancy test

          -  Use of oral/parenteral/inhaled corticosteroids within the last 28 days or injectable
             depot corticosteroids within the last 6 weeks.

          -  Use of any other asthma-related medications within 1 month of Screening
Clinical trial NCT01241422 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: jnj 40929837, placebo, montelukast
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria: - Generally healthy - Have mild atopic asthma requiring no other
        treatment besides occasional short-acting beta-2-agonists - Have allergen-induced early
        asthmatic response of at least a 20 percent reduction in forced expiratory volume in 1
        second (FEV1) and late asthmatic response of at least a 15 percent reduction in FEV1 during
        bronchial allergen challenge performed at screening - Females who are post menopausal,
        surgically sterilized, or practicing a highly effective method of birth control - Have an
        FEV1 at screening visit at least 75 percent of the predicted value - Have a history of
        asthma symptoms during exposure to indoor or outdoor allergens and a positive prick skin
        test done at the study site to dust mite, mixed grass pollen, or cat dander Exclusion
        Criteria: - Worsening of asthma or a respiratory tract infection within 6 weeks - HIV or
        Hepatitis B or C positive - Receipt of an investigational drug or use of an investigational
        medical device within the last month - Use of tobacco products of any kind currently or
        within 6 months - Have clinically significant abnormal physical examination, vital signs,
        or 12 lead electrocardiogram at screening as deemed appropriate by the investigator
Clinical trial NCT01094496 (phase 2, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    portfolio prioritization due to slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

        Among other criteria, patients must meet all of the following conditions to be eligible to
        be in the study:

          1. 18 years of age or older.

          2. Newly diagnosed muscle-invasive transitional cell (urothelial) bladder cancer where
             neoadjuvant chemotherapy and radical cystectomy with curative intent are indicated
             (i.e., American Joint Committee on Cancer (AJCC) stage T2-4a, Nany, M0). Patients must
             be entered into the study within eight weeks of their most recent diagnostic
             procedure, which is usually a diagnostic biopsy or transurethral resection of bladder
             tumor (TURBT) procedure.

          3. Histopathologically confirmed, transitional cell (urothelial) carcinoma. Urothelial
             tumors with mixed histology (but with <50% variant) are eligible.

          4. Tumor tissue (obtained during a prior procedure) confirmed to express hCG-β by a
             central laboratory.

          5. Candidate for therapy with neoadjuvant chemotherapy.

        Exclusion Criteria:

        Among other criteria, patients who meet any of the following conditions are NOT eligible to
        be in the study:

          1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior
             immunotherapy or intravesical (administered within the bladder) chemotherapy for
             superficial disease is acceptable.

          2. History of anaphylactic reaction following exposure to humanized or human therapeutic
             monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products,
             clinically meaningful allergic reactions to imiquimod, resiquimod, or any known
             hypersensitivity or prior reaction to any of the formulation excipients in the study
             drugs.

          3. Concurrent chronic treatment with immunosuppressive or immunomodulatory agents,
             including any systemic steroid (exception: inhaled or topically applied steroids, and
             acute and chronic standard dose NSAIDs, are permitted).

          4. Known infection with HIV, HBV or HCV.

          5. Any underlying medical condition that, in the Investigator's opinion, will make the
             administration of study vaccine hazardous to the patient, would obscure the
             interpretation of adverse events, or would contraindicate receipt of neoadjuvant
             chemotherapy or surgical resection.
Clinical trial NCT01171326 (phase 2, status: completed)
Conditions: impetigo
ICD codes: L01.00, L01.02, L01.03, L01.09, L01.01
Drugs: topical minocycline foam fxfm244
SMILES: [H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or
             uncomplicated blistering impetigo

          -  Patients 2 years of age or older, and in general good health

          -  Patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm.

          -  No known medical conditions that, in the Investigator's opinion could interfere with
             study participation

          -  Patient / Patient's guardian (in the case of children) willing and able to comply with
             all requirement of the protocol

          -  Patient / Patient's guardian willing and able to give written informed consent prior
             to participation in the study

        Exclusion Criteria:

          -  Presence of skin diseases at or near the investigational area

          -  Immunosuppressed state or other serious systemic disease

          -  Signs and/or symptoms of systemic infection

          -  Presence of skin infection/disorder not amenable to topical antibacterial treatment
             only

          -  Presence of secondarily-infected animal/human bite

          -  Presence of secondarily infected burn wound

          -  Topical or systemic use of medicinal or other products before or during the study
             (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators);
             or other drugs, which in the Investigators opinion could confound the evaluation of
             the effect of the study drugs

          -  Known or suspected hypersensitivity to Minocycline or any of the excipients in the
             study medication

          -  Participation in any other investigational drug study or use of (an) investigational
             drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to
             randomization

          -  Patients previously enrolled/randomized in this study

          -  Use of another investigational drug within 30 days prior to entry into this study.

          -  Pregnant or lactating women.
Clinical trial NCT00403273 (phase 2, status: completed)
Conditions: knee pain
ICD codes: M25.561, M25.562, M25.569
Drugs: botulinum toxin a, normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects, 18 years of age or older.

          -  Written informed consent and written authorization for use or release of health and
             research study information have been obtained.

          -  Subject has chronic Prosthetic knee joint pain for more than 3 months.

          -  Subject has pain 6 or greater on a 10 point Numerical Pain Rating scale

          -  Ability to follow study instructions and likely to complete all required visits.

          -  Negative urine pregnancy test on the day of treatment prior to the administration of
             study medication (for females of childbearing potential). (if applicable)

          -  Negative infectious etiology workup (joint aspiration, serological parameters such as
             Erythrocyte Sedimentation Rate (ESR) or C-reactive protein (CRP) and clinical
             examination).

          -  Patients who were considered not to be candidates for Prosthetic knee joint revision
             surgery and have failed traditional treatments including oral pain medications, as
             determined by referring orthopedic surgeon

        Exclusion Criteria:

          -  Use of aminoglycoside antibiotics, curare-like agents, or other agents that might
             interfere with neuromuscular function.

          -  Any medical condition that may put the subject at increased risk with exposure to
             BOTOX ®including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic
             lateral sclerosis, or known disorders of neuromuscular function

          -  Females who are pregnant, breast-feeding, or planning a pregnancy during the study or
             who think that they may be pregnant at the start of the study, or females of
             childbearing potential who are unable or unwilling to use a reliable form of
             contraception during the study.

          -  Know allergy or sensitivity to any of the components in the study medication.

          -  History of recent or ongoing alcohol or drug abuse.

          -  Known, uncontrolled systemic disease.

          -  Concurrent participation in another research study

          -  Any condition or situation that, in the investigator's opinion, may put the subject at
             significant risk, confound the study results, or interfere significantly with the
             subject's participation in the study.

          -  Patients whose pain is rated as less than 6 on a 10 point Numerical Pain Rating scale
             at the screening visit
Clinical trial NCT00716092 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo (linagliptin), placebo (linagliptin), sitagliptin, placebo (sitagliptin), placebo (sitagliptin), linagliptin
SMILES: CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Male and female patients with a diagnosis of type 2 diabetes mellitus and previously
             treated with not more than one drug

          -  Glycosylated haemoglobin A1 (HbA1c) 6.5 to 10.0% at Start of Run-in

        Exclusion criteria:

          -  Myocardial infarction, stroke or transient ischemic attack "TIA" within 6 months prior
             to informed consent

          -  Impaired hepatic function

          -  Renal insufficiency with a creatinine clearance < 50 mL/min

          -  Treatment with rosiglitazone, pioglitazone, glucagon like peptide 1 (GLP-1) analogues,
             insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors or anti-obesity drugs 3 months
             prior to informed consent.
Clinical trial NCT00190723 (phase 2, status: completed)
Conditions: malignant glioma
ICD codes: R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0
Drugs: enzastaurin
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  You must be at least 18 years old

          -  You must have been diagnosed with a recurrent brain tumor by MRI or CT scan

          -  You must be able to swallow the LY317615 tablets

        Exclusion Criteria:

          -  You are a woman who is pregnant or breastfeeding

          -  In view of your doctor, you have significant heart, liver, kidney, or psychiatric
             disease
Clinical trial NCT00478218 (phase 2, status: completed)
Conditions: multiple myeloma and plasma cell neoplasm
ICD codes: C96.20, C96.29, D47.09
Drugs: cyclophosphamide, dexamethasone, lenalidomide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma

               -  Newly diagnosed disease

               -  Symptomatic disease

          -  Measurable or evaluable disease, defined by ≥ 1 of the following criteria:

               -  Serum monoclonal protein ≥ 1.0 g by protein electrophoresis

               -  Monoclonal protein > 200 mg by 24-hour urine electrophoresis

               -  Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum
                  immunoglobulin kappa to lambda free light chain ratio

               -  Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)

               -  Measurable soft tissue plasmacytoma not previously irradiated

          -  No monoclonal gammopathy of undetermined significance or smoldering myeloma

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 (ECOG PS 3 allowed if secondary to pain)

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Hemoglobin ≥ 8.0 g/dL

          -  Creatinine ≤ 2.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception (1 highly effective
             and 1 additional method) for 1 month before, during, and for 4 weeks after completion
             of study therapy

          -  No uncontrolled infection

          -  No other active malignancy

          -  No other malignancies within the past 5 years except for currently treated basal cell
             or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast

          -  No NYHA class III-IV congestive heart failure

          -  No untreated active deep vein thrombosis

        PRIOR CONCURRENT THERAPY:

          -  At least 3 weeks since prior radiotherapy for solitary plasmacytoma

          -  Prior clarithromycin, therapeutic dehydroepiandrosterone (DHEA), anakinra, pamidronate
             disodium, or zoledronic acid allowed

          -  No prior cytotoxic chemotherapy

          -  No prior corticosteroids (except for treatment of a nonmalignant disorder)

          -  Concurrent corticosteroids (prednisone ≤ 20 mg/per day) allowed

          -  No concurrent radiotherapy except palliative radiotherapy for a single painful bone
             lesion or fracture
Clinical trial NCT00228995 (phase 2, status: terminated)
Conditions: anemia, aged, hemoglobins
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    this study was stopped due to slow enrollment after enrolling only 9 of 80 patients over 14
    months time.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a history of chronic anemia defined as a documented Hb value of <= 11.0
             g/dL

          -  No active cancer

          -  At least 65 years of age with life expectancy of > 6 months

          -  Community dwelling patients

          -  Patients with a Short Physical Performance (SPPB) Summary Score of 4-10 at screening
             and baseline

          -  Patients with a Mini Mental State Examination (MMSE) score >= 24

        Exclusion Criteria:

          -  Positive stool guaiac test

          -  Diagnosis of multiple myeloma and/or MGUS

          -  History of venous thromboembolytic disease

          -  Previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin
             recently

          -  Uncontrolled or severe cardiovascular disease
Clinical trial NCT00296959 (phase 2, status: terminated)
Conditions: parkinson's disease
ICD codes: G20
Drugs: topiramate (drug)
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Reason stopped: 
    early termination due to slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  UK PD Society Brain Bank criteria for the diagnosis of idiopathic PD.

          -  Patients with stable levodopa-induced dyskinesias present greater than 25% of the day
             (Unified Parkinson's Disease Rating Scale (UPDRS), item 32, rating > 2) and be
             moderately to completely disabling (UPDRS item 33, rating > 2).

          -  All anti-parkinsonian medications must be stable for at least one month prior to study
             enrollment.

        Exclusion Criteria:

          -  Include prior surgery for PD

          -  Hoehn and Yahr score of 5 when "off"

          -  History of nephrolithiasis

          -  Renal impairment

          -  Liver disease

          -  Pregnancy

          -  Premenopausal females and males not using adequate contraception

          -  Cognitive impairment (Mini Mental State Exam score less than 24)

          -  History of glaucoma or seizures

          -  Use of other antiepileptic drugs

          -  Amantadine

          -  Carbonic anhydrase inhibitors

          -  Digoxin

          -  Metformin

          -  Or illicit drugs
Clinical trial NCT00552188 (phase 2, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: via-2291, placebo
SMILES: C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  Female patients must be of non-childbearing potential

          -  Recent acute coronary syndrome [(ACS) ST elevation myocardial infarction (STEMI),
             non-STEMI or unstable angina) event documented by ECG, cardiac enzymes or angiogram] 1
             - 3 months prior to randomization

          -  Carotid or ascending aorta artery plaque inflammation Target-to-Background Ratio (TBR)
             ≥ 1.6

          -  Receiving concomitant statin therapy following the qualifying ACS event for a minimum
             of 4 weeks, including a stable statin dose regimen for 2 weeks prior to randomization.

        Exclusion Criteria

          -  Renal insufficiency defined as creatinine >1.5 x upper limit of normal (ULN)

          -  Cirrhosis, recent hepatitis, alanine aminotransferase (ALT) >1.5 x ULN (i.e., above
             the normal range) or positive screening test for hepatitis B (hepatitis B surface
             antigen) or hepatitis C (by ELISA)

          -  Type I diabetes and uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) >
             9%

          -  Heart failure defined by New York Heart Association Class III or IV

          -  Coronary Artery Bypass Surgery (CABG) within 4 months of randomization

          -  Use of zileuton, montelukast, coumadin or steroids

          -  Acetaminophen use in any form in the 7 days before enrollment at Visit 1

          -  Allergy to contrast agents

          -  Planned additional cardiac intervention (e.g., PCI, CABG) within next 6 months

          -  Current atrial fibrillation, atrial flutter or frequent premature ventricular
             contractions
Clinical trial NCT00367744 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: rosiglitazone, placebo
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Lipoatrophy

          -  Thymidine sparing ARV for at least 24 weeks

          -  Prior thymidine NRTIs for at least 12 months

        Exclusion Criteria:

          -  Diabetes

          -  Heart failure

          -  Liver disease

          -  Hormonal therapies
Clinical trial NCT01213368 (phase 2, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: dronedarone (sr33589), placebo
SMILES: CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients of aged 20 years or more.

          -  Permanent Atrial Fibrillation [AF] (defined as duration of AF > 6 months) for which
             cardioversion is not considered and with resting ventricular heart rate ≥ 80 bpm at
             screening.

        Exclusion criteria:

          -  Unstable angina pectoris.

          -  History of torsades de pointes.

          -  Prolonged QT corrected interval (≥ 500 ms).

          -  Third degree atrioventricular block (AVB) on the screening ECG while in AF or,
             documentation on previous ECGs while in sinus rhythm of PR-interval > 0.28 sec or high
             degree AVB (2nd degree or higher) or, significant sinus node disease (documented pause
             ≥ 3 sec) - without a permanent pacemaker implanted.

          -  Congestive Heart Failure (CHF) of New York Heart Association classification (NYHA)
             class IV or recent (within 1 month prior to randomization) unstable NYHA class III.

          -  Treatment with other class I or III anti-arrhythmic drugs.

          -  Patients treated with amiodarone during the 4 weeks preceding randomization.

          -  Clinically relevant haematologic, hepatic, gastro-intestinal, renal, pulmonary,
             endocrinologic (in particular thyroid) or psychiatric disease.

          -  Hypokalemia and hypomagnesemia must be corrected before randomization.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.